Science translational medicine [Sci Transl Med] 2025 May 21; Vol. 17 (799), pp. eado1641. Date of Electronic Publication: 2025 May 21.
Utgivningstyp:
Journal Article
Tidskrift info:
Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Pr
Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Imprint Name(s):
Original Publication: Washington, DC : American Association for the Advancement of Science
Historically, DNA sequence mutability has been considered relatively uniform and low in tumors with chromosomal instability (CIN), based on
Historically, DNA sequence mutability has been considered relatively uniform and low in tumors with chromosomal instability (CIN), based on the assumption that high mutability would be detrimental in karyotypically aberrant contexts. Recent in silico analyses have challenged this view, suggesting some heterogeneity in mutation rates across CIN tumors; however, these predictions lack experimental validation. It also remains unclear how the intertumor variability of mutation rates compares to intratumor diversification and evolves along disease progression, whether mutation rates are functionally relevant in CIN cancers, and which mutational processes shape mutational accrual during CIN tumor onset and evolution. To address these gaps, we performed mutation accumulation experiments using clonal populations of patient-derived tumoroids from seven CIN, microsatellite-stable colorectal cancers (CRCs), and one microsatellite-unstable CRC. Each tumor exhibited a distinctive mutation rate footprint that was conserved among different clones from the same ancestor. In contrast, mutation rates diverged markedly across different tumors, with variations in magnitude within microsatellite-stable tumors as prominent as those distinguishing them from microsatellite-unstable tumors. New mutations reflected mutational processes associated with defective DNA replication and repair, which were not detected in normal tissues. Last, both mutation accumulation assays and high-depth whole-exome sequencing of subclonal variants showed higher mutation rates in metastatic lesions compared with matched primary tumors, suggesting positive selection for cells with increasing mutability during cancer dissemination. By providing an empirical assessment of mutation rates in human cancer, our data delineate heterogeneity, heritability, and progression-associated evolvability of DNA mutational instability as hallmarks of microsatellite-stable CRC.
Entry Date(s):
Date Created: 20250521 Date Completed: 20250521 Latest Revision: 20250521
Update Code:
20250522
Databas:
MEDLINE
Författarna:
Grassi E; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Vurchio V; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Cresswell GD; Centre for Evolution and Cancer, Institute of Cancer Research, London SW7 3RP, UK.; St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria., Catalano I; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Lupo B; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Sassi F; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Galimi F; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Borgato S; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Ferri M; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Viviani M; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Pompei S; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy., Urgese G; Interuniversity Department of Regional and Urban Studies and Planning, Polytechnic University of Torino, 10129 Torino, Italy., Chen B; Centre for Evolution and Cancer, Institute of Cancer Research, London SW7 3RP, UK.; GMU-GIBH Joint School of Life Sciences, Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, 510580 Guangzhou, China., Zanella ER; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Cottino F; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Russo M; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy.; Department of Oncology, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy., Mauri G; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy.; Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy., Zampino MG; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology IRCCS, 20141 Milano, Italy., Lazzari L; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy., Marsoni S; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy., Bardelli A; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy.; Department of Oncology, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy., Lagomarsino MC; IFOM ETS-AIRC Institute of Molecular Oncology, 20139 Milano, Italy., Sottoriva A; Centre for Evolution and Cancer, Institute of Cancer Research, London SW7 3RP, UK.; Computational Biology Research Centre, Human Technopole, 20157 Milano, Italy., Trusolino L; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy., Bertotti A; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.; Candiolo Cancer Institute-FPO IRCCS, 10060 Candiolo, Torino, Italy.